Lisata Therapeutics disclosed Tuesday that Kuva Labs, the diagnostics subsidiary it agreed to acquire in December, is actively seeking new financing and has not commenced the previously announced tender offer. The announcement marks the second significant delay in a transaction that was supposed to close in Q1 2025 with a $15 million upfront payment.

Kuva Labs, a pre-revenue company developing fluorescence imaging technology for surgical guidance, was structured as a share-for-share merger with Lisata issuing approximately 18 million shares at signing. The tender offer—designed to allow existing Kuva shareholders liquidity before merger close—was originally planned for January but has not materialized. Lisata's disclosure provides no timeline for when the offer might launch, citing only that Kuva "is seeking new financing" without specifying amount or terms.

The financing hunt suggests Kuva's burn rate has accelerated beyond expectations or that prior funding commitments fell through. Companies at this stage typically require $3-7 million annually to maintain clinical trial momentum and regulatory filings. Lisata itself reported $12.8 million in cash at September 30, 2024, with quarterly burn near $4 million, leaving limited room to backstop Kuva's operations pre-close. The absence of a tender offer means existing Kuva investors remain locked in an illiquid position while the parent company's stock—down 68% over twelve months—continues to trade.

The transaction was pitched as Lisata's pivot from its stalled LSTA1 cancer therapy toward commercializable diagnostics. Kuva's lead product, a fluorescence imaging agent for tumor margin detection during surgery, remains in preclinical and early feasibility studies with no FDA approval timeline disclosed. The merger agreement included standard material adverse effect clauses, but Lisata has not indicated any intent to renegotiate or terminate despite the financing complications.

Operators should watch for two near-term catalysts: any Form 8-K filing disclosing Kuva's financing terms or lender identity, and Lisata's Q4 2024 earnings call, expected mid-March, where management will face direct questions about deal viability. If Kuva cannot secure financing within 60-90 days, Lisata may face a binary decision between injecting its own capital—risking a going-concern opinion—or walking away and absorbing deal-break costs.

The tender offer delay is now longer than the original contemplated merger timeline, a fact that speaks louder than any press release.